JPS62100661A - Discovery of cancer - Google Patents

Abstract

PURPOSE:To enable earlier discovery of cancer accurately, by combining analysis values obtained by quantitative analyses on cancer specific tumor marker, on a tumor marker attributed to a living body and on tumor-related antigen. CONSTITUTION:A cancer specific tumor marker is a protein intrinsic to cancerous cells produced from the cancerous cells when changed from normal cells. For this marker, for example, heat resistant alkali phosphatase, cancerous embryo antigen, ferritin and the like are selected. On the other hand, for tumor marker attributed to living bodies, sialate, IAP, ferritin and the like are selected. These undergoes a quantitative analysis by electrophoresis, colorimetry and the like; moreover, the tumor-related antigen does. The analysis values obtained are combined and compared with a preset reference value to judge on the presence of cancerous cells. Thus, initial diagnosis of cancer can be achieved.

Description

[Detailed description of the invention] The present invention relates to a method for early detection of cancer.

Conventionally, cancer tests have been performed by extracting cancer-specific tumor markers produced by cancer cells from blood and analyzing them by means such as electrophoresis. However, by the time cancer-specific tumor markers are produced, cancer cells have already increased considerably, so it is too late and recurrence often occurs even after surgery, making it an essential early detection tool. There wasn't. Also, cancer-specific llIr! CEA is derived from cancer cells of the gastrointestinal tract or the organ system; CEA is derived from lung cancer cells such as CA19/9.
is determined by the site of onset of the cancer, so that when testing only a specific cancer-specific tumor marker, 1) [If there is no evidence of the onset status of other sites of cancer] There wasn't.

The present inventors have proposed combining the analysis values of biological tumor markers and tumor-related antigens, which are generated in vivo when cancer cells proliferate, with the analysis values of cancer-specific tumor-7-forces, and are aiming at reversible abnormal cells (microcarcinoma). The present invention was completed on the basis of this finding.

That is, the present invention combines the two analysis values obtained by quantitative analysis of cancer markers, biogenic tumor markers, and tumor-related antigens, and compares them with preset standard values to determine whether the tumor is a small cancer. It is characterized by testing for the presence or absence of reversible abnormal cells.

The present invention will be further explained below. 6. Cancer-specific markers 11 Tumor markers are proteins unique to cancer cells that are produced by cancer cells when normal cells turn into cancer cells.
For example, N1fA alkaline phasphatase (H8AP), carcinoembryonic antigen (CEA), ferritin, etc. may be selected as this marker. On the other hand, sial salts and TAP are used as biological Hf1 tumor markers.

Ferrisen et al. are selected. These are electrophoresis.

Quantitative analysis is performed using a colorimetric method or the like, and furthermore, tumor-associated antigens are quantitatively analyzed in the present invention. The obtained analysis values are combined,
The presence or absence of cancer cells is determined by comparing with a preset standard value. This allows for early diagnosis of cancer.

FIG. 1 shows standard values set in advance.

In the figure, the horizontal axis is the number of cancer cell generations, and the vertical axis is the number of cancer cells. N is the normal biological range, μ is cancer at the μg level, M
,, M engineering is mg level cancer, 60 to G-1 is Durham level cancer, and 60 or above is a clinical disease that requires surgery. The present invention uses the above analytical values to detect cancer at the micro level (μ).
) and cancer at the mg level (M,.

M2) can be discovered. Since markers and antigens related to cancer cells have a certain relationship, by combining them, it is possible to discover the level of cancer before symptoms appear.

Table 1 below is an example of a standard table that is predetermined to determine what level a patient is at by combining the markers and antigens as described above. This table shows examples of combinations within the range of Myu to G1 in Table 1, but it can be similarly applied to the μ level and mg level.

(Margins below) Therefore, this table allows objective judgment of the level at which the pain symptoms have reached, making it possible to make an accurate diagnosis. As a result, when a patient is at the μt level or M level, by ingesting anticancer substances and their promoting factors and avoiding s1-s, the proliferation of cancer cells can be prevented through the body's immune-inducing effect. On the other hand, at the G level, it becomes clear that treatment methods such as deletion of cancer cells and radiation irradiation are required.

FIG. 2 shows a characteristic diagram when analyzing each molecular type of the ALP isozyme and combining the analytical values. This analysis is performed as follows. The ALP isozyme angle (A P
-A) is measured and used as an indicator of the test. In other words, the judgment in the same figure (,) is a case where the AL floor is not recognized, and the A
The line connecting the peaks of L PX and ALP□ and A L P
Let the angle between i and the tangent on the anode side be θ1, and from this intersection A
AP-p-α with the distance to the peak of LP□ being 0 cm
/θ1 is obtained. On the other hand, if the existence of A L P is considered, the tangent line of A L pHL and A
Let the angle with the tangent of LP□ be the slope, and from the intersection point A L
AP-A-β/ where the distance to the peak of Pv is βcm
Let it be θ2.

In addition, the combination in the present invention can be performed not only on the above-mentioned ALP but also on any of cancer-specific tumor markers including CEA, -ferritin, etc., biological tumor markers, and M cancer-related antigens, depending on the clinical case. By comparing the results with a standard value table prepared in advance according to clinical cases, early cancer can be detected easily and reliably.

Therefore, according to the present invention, since early detection of cancer can be reliably performed, treatment can be performed according to the symptoms, and early treatment of cancer is possible.

[Brief explanation of drawings]

Figure 1 is an example of a standard value table that can be applied to the present invention;
Figures (a) and (b) are based on the ALP analysis results.
It is a characteristic diagram to obtain A.

Claims (1)

[Claims] Combining the analytical values obtained by quantitative analysis of cancer-specific tumor markers, biological tumor markers, and tumor-related antigens,
1. A method for detecting cancer, comprising testing for the presence or absence of reversibly abnormal cells by comparing with a preset standard value.